Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 496.78% and ...

The president-elect is set to appear with SoftBank Group CEO Masayoshi Son at Mar-a-Lago on Monday. The industrial conglomerate said its board continued to explore strategic alternatives and plans to ...

The monthslong battle over the future of the weight-loss drug industry is headed for a climax this week, when the Food and ...

Mike Plante struggled with his weight for years, but within six months of starting with the injection drug semaglutide, a ...

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. In recent years, these two healthcare leaders ...

Eli Lilly ( LLY 0.86%) is a screaming buy because it makes the most potent weight-loss drug that's on the market right now, ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss ...

A few years ago, West Virginia, which has the highest obesity rate in the nation, quietly began a small and unusual pilot ...